Hironic Co

Hironic Co EBITDA per Share

The EBITDA per Share of Hironic Co (149980.KQ) as of Oct 30, 2026 is 327.12 KRW. In the previous year, EBITDA per Share was -457.54 KRW — a change of -171.50% (higher).

EBITDA per Share

327.12KRW

YoY

-171.50%

Last updated:

EBITDA per Share of Hironic Co is 2025 327.12 KRW. EBITDA per Share of Hironic Co was 2024 -457.54 KRW. It decreases by -171.50% higher compared to the previous year.

The Hironic Co EBITDA per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA per Share
Date
EBITDA per Share
Jan 1, 2018
47.32 KRW
Jan 1, 2019
258.98 KRW
Jan 1, 2020
144.10 KRW
Jan 1, 2021
398.47 KRW
Jan 1, 2022
321.99 KRW
Jan 1, 2023
812.53 KRW
Jan 1, 2024
-457.54 KRW
Jan 1, 2025
327.12 KRW
The Hironic Co EBITDA per Share history
YEAREBITDA per ShareYoY
327.12KRW-171.50%
-457.54KRW-156.31%
812.53KRW+152.35%
321.99KRW-19.19%
398.47KRW+176.53%
144.10KRW-44.36%
258.98KRW+447.26%
47.32KRW-73.93%
181.55KRW+170.37%
67.15KRW-64.57%
189.52KRW-69.36%
618.49KRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Hironic Co Stock analysis

What does Hironic Co do? Hironic Co., Ltd. generates revenue through the manufacture and sale of medical equipment for skin and obesity care. The company's product lineup includes MIXEL, designed for treating skin lesions and melasma while enhancing skin texture and tone; MIPL, which addresses pigmentation, wrinkles, vascular issues, acne, and hair removal; MIDEPI, a dedicated hair removal device; DOUBLO, used for skin tightening, rejuvenation, and non-invasive facial and eyebrow lifting; MICOOL, for natural fat cell destruction; and New Midas, targeting body contouring and facial lifting. These products are sold to medical facilities and clinics specializing in dermatology and cosmetic treatments, with a focus on skin and obesity care segments. The company's revenue streams are derived from direct sales of its branded medical devices to healthcare providers. MIXEL and MIPL cater to dermatological treatments, while MIDEPI and MICOOL serve aesthetic and body contouring markets. DOUBLO and New Midas are positioned for non-invasive cosmetic procedures, appealing to clinics seeking advanced solutions for skin tightening and facial rejuvenation. Hironic's product portfolio targets both skin treatment and obesity care, aligning with the growing demand for specialized medical equipment in these sectors. Hironic Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Hironic Co stock

EBITDA per Share of Hironic Co is 327.12 KRW in 2025.

EBITDA per Share of Hironic Co changed from -457.54 KRW to 327.12 KRW, representing a -171.50% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBITDA per Share Hironic Co since 2006 – with annual values, charts, and detailed analysis.

EBITDA per share divides EBITDA by shares outstanding, showing the operating cash earnings allocated to each share before depreciation and financing effects.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Hironic Co

All Key Metrics — Hironic Co